a BavaRiAn eValuatiOn of Dorsal Root Ganglion (DRG) Stimulation for the Treatment for Chronic Post Surgical Pain of the Groin
TerminatedNCT02346656
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
15-SMI-2013 is a post market, observational, questionnaire based study to assess the effectiveness of the commercially available Axium neurostimulator in the management of chronic post surgical groin pain
Study details
- Official title
- BRAVO: a BavaRiAn eValuatiOn of DRG Stimulation for the Treatment for Chronic Post Surgical Pain of the Groin
- Conditions
- Post Surgical Groin Pain
- Sponsor
- Abbott Medical Devices
- Start date
- 2013-05
- Primary completion
- 2015-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Germany
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. The patient is at least 18 years old 2. The patient is willing and able to comply with the examination schedule and the trial schedule. 3. The patient has suffered from chronic post-surgical neuropathic groin pain for at least 6 months 4. Conservative treatments of the chronic pain including medication, physiotherapy and interventions have been exhausted 5. The pain level at the time of the baseline examination is at least 60mm on the visual analogue scale (VAS) in the primary pain area (groin pain) 6. The patient is able to give consent in writing Exclusion Criteria: 1. Pregnant or breastfeeding patients or those who plan to become pregnant during the study 2. It has been established in an examination by the tester that the pain has significantly worsened or changed its characteristics in the course of the previous month. 3. In the last 30 days, the patient has been treated with corticosteroids on an area scheduled for the stimulation. 4. In the last 3 months, the patient has been treated with radio frequency therapy on an area scheduled for the stimulation. 5. The patient has already been treated with an active implantable device, including an implantable cardioverter defibrillator, pacemaker, spinal cord stimulator or an intrathecal medication pump. 6. The patient is not able to operate the stimulation device 7. The patient is currently suffering from an infection 8. The patient has participated in another clinical study in the last 30 days 9. The patient has a coagulation disorder or is taking anti-coagulants, which would make participation impossible, as per the study doctor 10. The patient has been diagnosed with a malignancy in the past 2 years
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02346656